Recruiting

Octane Aether

Sponsor:

Octane Innovation Inc.

Code:

NCT07614568

Conditions

Non-specific Chronic Low Back Pain

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Pulsed electromagnetic field stimulator

Study Details

Brief summary:

The goal of this clinical trial is to evaluate the safety of the Octane Aether device and to determine whether the device is effective in treating symptoms of non-specific chronic low back pain in adults. The Octane Aether is a wearable device that produces specific magnetic field outputs and is designed for daily use in a home setting. The main objectives of the trial are:

  • To measure the change in patient-reported pain scores during active treatment with the device compared to a sham treatment, and
  • To define and describe the adverse effects, if any, of the Octane Aether device when administered according to the protocol.

Every participant will evaluate three active output modes and a sham output using the same device. Patient-reported outcomes will inform the effectiveness of each output mode and help identify the need for personalization in magnetic field therapy.

Participants will:

  • Use the device at home for 60 minutes every day for 10 weeks,
  • Report daily pain scores using an electronic visual analog scale for pain intensity,
  • Visit the clinic 5 times over the course of the 13 week trial for checkups and device changes,
  • Respond to 3 phone calls for checkups, and
  • Fill various questionnaires related to disability, quality of life, and their back pain.

Conditions

Non-specific Chronic Low Back Pain

Study ID

NCT07614568

Start date

Oct 15, 2026

Status verified date

Nov, 2026

Completion date

Jul, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Able to provide informed consent;
  • Aged 18-65;
  • Pain intensity of at least 5 on a numerical rating scale (0-10);
  • Experiencing chronic low back pain that has persisted for ≥3 months;
  • Pain localized primarily to the lumbar spine region;
  • Conservative treatments, such as physical therapy, NSAIDs and lifestyle changes, have failed over the past 6 months. Participants are allowed to continue conservative treatments, but changes to use/frequency will be tracked; and
  • Must be able to attend 5 in-person clinic appointments over the 13-week study period.

Exclusion Criteria:

  • Began using new prescription medication for pain within the past 3 months;
  • Lumbar spine surgery (within the past 12 months);
  • Body Mass Index (BMI)> 35. The device may have diminished effectiveness and/or may not fit individuals with high BMI;
  • Presence of a cardiac pacemaker;
  • Pregnancy or breastfeeding;
  • Presence of ferromagnetic implants or body piercings (e.g., navel piercings) in the lumbar region, including hip implants/replacements or similar in the pelvic region, that could interfere with device function;
  • Inability to put on, adjust, and/or operate the wearable device without assistance;
  • Prior use of PEMF, or other electromagnetic field-emitting device, for the treatment of pain symptoms;
  • No, or inconsistent, access to internet (emailed surveys are used for daily data collection); and
  • Any condition or diagnosis that could in the opinion of the Principal Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk.

Study Design

Enrollment

24 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Sequence Group 1

Participants receive active/sham treatments in the following sequence: EMF A, EMF B, Sham, EMF C

experimental: Sequence Group 2

Participants receive active/sham treatments in the following sequence: EMF B, EMF C, EMF A, Sham

experimental: Sequence Group 3

Participants receive active/sham treatments in the following sequence: EMF C, Sham, EMF B, EMF A

experimental: Sequence Group 4

Participants receive active/sham treatments in the following sequence: Sham, EMF A, EMF C, EMF B

Interventions

Pulsed electromagnetic field stimulator

The Octane Aether is a body-worn device that generates pulsed magnetic fields of specific characteristics designed to target cellular behaviour in relation to chronic pain signalling. The device features four different output modes (3 active and 1 sham) to enable an investigation of the need for personalized pain management. The specific characteristics of the output modes are blinded from the participants and study team and are labelled here as EMF A, EMF B, EMF C, and Sham. The device firmware is programmed to automatically change the output mode every two weeks. The device produces no sound or thermal effects.

When operating in the sham mode, the device appears identical to active output, but no current is applied to the body-worn coil applicator and no magnetic field is generated.

Primary outcome measure

  • Change in patient-reported pain scores during active treatment compared to the sham treatment period [ Time Frame: From start of Treatment Period 1 (Week 2) to end of Treatment Period 4 (Week 9) ]

Central Contacts and Locations

Locations

Kingston Orthopaedic Pain Institute

Recruiting

Kingston, Ontario, Canada, K7K 0J7

Contacts

Principal Investigator:

Thomas Gregory

More Information

Sponsor

Octane Innovation Inc.

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Keywords

  • low back pain
  • Electromagnetic field stimulation
  • Octane Aether
  • Pain management
  • EMF therapy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Octane Innovation Inc. on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.